Affiliation:
1. SOMPS, Salpêtrière Hospital, Department of Medical Oncology, Paris, France
2. Centre Charlebourg, la Garenne-Colombes, France
Abstract
Abstract
Most cases of advanced carcinoma of the prostate are hormonosensitive. The use of combined androgen blockade (CAB) seems to improve survival and quality of life, but only when combined with chemical castration by luteinizing-hormone-releasing hormone analog and without the use of steroidal antiandrogens. After CAB, further hormonal treatments remain efficacious, such as antiandrogen withdrawal followed by estrogens, aromatase inhibitors, and hormone-refractory prostate cancer multiple cytotoxic agents. For painful bone lesions, external beam radiotherapy, biphosphonates, and strontium 89 or samarium 153 provide pain relief. The use of new methods for the evaluation of response and quality of life will allow the rapid identification of effective treatments and permit powered phase III trials.
Publisher
Oxford University Press (OUP)
Reference54 articles.
1. Adenocarcinoma of the prostate: innovations in management;Petrovich;Am J Clin Oncol,1997
2. Cancer statistics, 1996;Parker;CA Cancer J Clin,1996
3. Epidémiologie du cancer de la prostate et ses implications en santé publique;Richard;Rev Prat,1994
4. Cancer statistics, 1999;Landis;CA Cancer J Clin,1999
5. Treatment of progressive metastatic prostate cancer;Dawson;Oncology,1993
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献